Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2020
Reporting Period: Events occurring between January 27, 2020, and January 31, 2020.
Status: Emerging Growth Company.
Key Financial Metrics
This filing reports on a specific capital transaction rather than periodic financial performance. Consequently, the document does not provide data on revenue, profit, cash flow, operating margins, or overall liquidity.
| Metric | Value |
|---|---|
| Debt Converted (Current Period) | $205,166 (inclusive of accrued interest) |
| Shares Issued (Current Period) | 201,436,602 shares of common stock |
| Debt Converted (Prior Jan 2020) | $656,210 (inclusive of accrued interest) |
| Shares Issued (Prior Jan 2020) | 304,532,285 shares of common stock |
Material Changes
The primary material change reported is the unregistered sale of equity securities via the conversion of debt.
- Debt-to-Equity Conversion: Between January 27 and January 31, 2020, the Company issued 201,436,602 shares of common stock to holders of convertible promissory notes in exchange for $205,166 of outstanding indebtedness.
- Recent History: This follows a series of similar conversions in early January 2020 (reported on Jan 7, 10, 16, and 24), where 304,532,285 shares were issued for $656,210 of debt.
- Capital Structure Impact: These transactions significantly increased the number of outstanding shares while reducing the Company's short-term debt obligations.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction mechanics.
- Regulatory Basis: The Company relied on Section 4(a)(2) of the Securities Act of 1933 (transactions not involving a public offering) and Section 3(a)(9) (exchange with existing security holders) to exempt the issuance from registration.
- Investor Status: The Company reasonably believes all investors in these transactions are accredited investors.
- Information Access: Investors were provided access to the Company's 2018 Form 10-K, 2019 Form 10-Qs, and prior 8-K filings.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion to assess potential dilution impact.
- Review the terms of the convertible promissory notes to understand the conversion price and interest rates applied.
- Confirm the Company's remaining cash position and outstanding debt after these conversions, as this filing does not provide a balance sheet.
- Check subsequent filings for any further debt conversions or liquidity events given the high volume of share issuance in early January 2020.